文献速递淋巴瘤

Polatuzumab vedotin治疗复发/难治性弥漫大B细胞淋巴瘤

Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
PubMed 文献 · J Clin Oncol · 2019-11-06

这项研究评估了polatuzumab vedotin联合苯达莫司汀和奥妥珠单抗(pola-BG)或利妥昔单抗(pola-BR)在不适合移植的复发/难治性弥漫大B细胞淋巴瘤(DLBCL)患者中的安全性和疗效。pola-BR组相比BR组显著提高了完全缓解率(40.0% vs 17.5%),并延长了无进展生存期和总生存期。

要点

  • pola-BR组中位PFS为9.5个月 vs 3.7个月(HR 0.36,95%CI 0.21-0.63)。
  • pola-BR组中位OS为12.4个月 vs 4.7个月(HR 0.42,95%CI 0.24-0.75)。

核心结论

  • 在不适合移植的复发/难治性DLBCL患者中,pola-BR相比BR显著提高完全缓解率并降低死亡风险。

研究设计与样本

  • 单臂队列评估pola-BG的安全性和疗效,随机队列比较pola-BR与BR(主要终点为IRC评估的治疗结束时完全缓解率)。

主要发现

  • pola-BG队列(n=27)的完全缓解率为29.6%,中位OS为10.8个月(中位随访27.0个月)。
  • pola-BR组3-4级中性粒细胞减少(46.2% vs 33.3%)、贫血(28.2% vs 17.9%)和血小板减少(41% vs 23.1%)发生率更高,但3-4级感染率相似(23.1% vs 20.5%)。
  • 与polatuzumab vedotin相关的周围神经病变(43.6%的患者)为1-2级,大多数患者缓解。

临床怎么用

  • 对于不适合移植的复发/难治性DLBCL患者,可考虑使用pola-BR方案。
  • 使用pola-BR时需注意血液学毒性,尤其是3-4级中性粒细胞减少、贫血和血小板减少。
  • 应监测polatuzumab vedotin相关的周围神经病变,多为1-2级且可缓解。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Patients with transplantation-ineligible relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) fare poorly, with limited treatment options. The antibody-drug conjugate polatuzumab vedotin targets CD79b, a B-cell receptor component. METHODS: Safety and efficacy of polatuzumab vedotin with bendamustine and obinutuzumab (pola-BG) was evaluated in a single-arm cohort. Polatuzumab vedotin combined with bendamustine and rituximab (pola-BR) was compared with bendamustine and rituximab (BR) in a randomly assigned cohort of patients with transplantation-ineligible R/R DLBCL (primary end point: independent review committee [IRC] assessed complete response [CR] rate at the end of treatment). Duration of response, progression-free survival (PFS), and overall survival (OS) were analyzed using Kaplan-Meier and Cox regression methods. RESULTS: Pola-BG and pola-BR had a tolerable safety profile. The phase Ib/II pola-BG cohort (n = 27) had a CR rate of 29.6% and a median OS of 10.8 months (median follow-up, 27.0 months). In the randomly assigned cohort (n = 80; 40 per arm), pola-BR patients had a significantly higher IRC-assessed CR rate (40.0% v 17.5%; P = .026) and longer IRC-assessed PFS (median, 9.5 v 3.7 months; hazard ratio [HR], 0.36, 95% CI, 0.21 to 0.63; P < .001) and OS (median, 12.4 v 4.7 months; HR, 0.42; 95% CI, 0.24 to 0.75; P = .002; median follow-up, 22.3 months). Pola-BR patients had higher rates of grade 3-4 neutropenia (46.2% v 33.3%), anemia (28.2% v 17.9%), and thrombocytopenia (41% v 23.1%), but similar grade 3-4 infections (23.1% v 20.5%), versus the BR group. Peripheral neuropathy associated with polatuzumab vedotin (43.6% of patients) was grade 1-2 and resolved in most patients. CONCLUSION: Polatuzumab vedotin combined with BR resulted in a significantly higher CR rate and reduced the risk of death by 58% compared with BR in patients with transplantation-ineligible R/R DLBCL.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2019. PMID: 31693429. doi:10.1200/JCO.19.00172

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。